What is Zacks Small Cap’s Estimate for TELO FY2024 Earnings?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) – Stock analysts at Zacks Small Cap issued their FY2024 earnings per share estimates for shares of Telomir Pharmaceuticals in a research report issued on Thursday, November 21st. Zacks Small Cap analyst B. Sorensen forecasts that the company will post earnings per share of ($0.54) for the year. The consensus estimate for Telomir Pharmaceuticals’ current full-year earnings is ($0.54) per share. Zacks Small Cap also issued estimates for Telomir Pharmaceuticals’ Q4 2024 earnings at ($0.05) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.18) EPS.

Telomir Pharmaceuticals Price Performance

Shares of TELO opened at $4.45 on Monday. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $20.72. The firm has a 50-day moving average price of $4.97 and a 200 day moving average price of $4.97.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after buying an additional 5,367 shares during the period. Beaird Harris Wealth Management LLC raised its stake in Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after buying an additional 9,950 shares in the last quarter. State Street Corp raised its position in shares of Telomir Pharmaceuticals by 99.1% during the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $241,000. Finally, Suncoast Equity Management raised its stake in Telomir Pharmaceuticals by 109.9% during the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after acquiring an additional 26,803 shares in the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.